Gilead’s Tecartus escapes harsher classwide boxed warning for CAR-T therapies
The US FDA has requested a different safety label for Gilead’s Tecartus compared to other approved CAR-T cell therapies.
The US FDA has requested a different safety label for Gilead’s Tecartus compared to other approved CAR-T cell therapies.
What's Your Reaction?
